{
    "eid": "2-s2.0-84996607034",
    "title": "Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients",
    "cover-date": "2016-12-01",
    "subject-areas": [
        {
            "$": "Pharmacology (medical)",
            "@code": "2736"
        },
        {
            "$": "General Pharmacology",
            "@code": "3000"
        }
    ],
    "keywords": [
        "antiretroviral drugs",
        "HIV",
        "Therapeutic drug monitoring"
    ],
    "authors": [
        "Baralee Punyawudho"
    ],
    "citedby-count": 36,
    "ref-count": 150,
    "ref-list": [
        "Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection",
        "Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection",
        "Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study",
        "Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda",
        "Subtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care",
        "Viral suppression following switch to second-line antiretroviral therapy: Associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch",
        "The pharmacology of HIV drug resistance",
        "High variability of plasma drug concentrations in dual protease inhibitor regimens",
        "Plasma Concentrations of Efavirenz and Nevirapine among HIV-Infected Patients with Immunological Failure Attending a Tertiary Hospital in North-Western Tanzania",
        "Overview of therapeutic drug monitoring",
        "Antiepileptic drugs - Best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies",
        "Impact of vancomycin therapeutic drug monitoring on patient care",
        "Therapeutic drug monitoring for immunosuppressants",
        "Single-measurement therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, lamivudine, efavirenz, nevirapine, lopinavir and nelfinavir",
        "Concentration-controlled compared with conventional antiretroviral therapy for HIV infection",
        "Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.",
        "Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study",
        "Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.",
        "Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population",
        "Efavirenz and nevirapine in HIV-1 infection: Is there a role for clinical pharmacokinetic monitoring?",
        "Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action",
        "Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice",
        "Is it time to revise antiretrovirals dosing? A pharmacokinetic viewpoint",
        "High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma",
        "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents",
        "Use of therapeutic drug monitoring in HIV disease",
        "Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals",
        "A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients",
        "A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: Week 48 results of the A5146 study",
        "A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients",
        "GENOPHAR: A randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy",
        "PharmAdapt: A randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 Week results",
        "Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN) - A randomized controlled trial of therapeutic drug monitoring and adherence support",
        "Therapeutic drug monitoring in highly active antiretroviral therapy",
        "The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection",
        "Clinical pharmacodynamics of HIV-1 protease inhibitors: Use of inhibitory quotients to optimise pharmacotherapy",
        "Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: Can they applied to the current situation?",
        "Inhibitory quotient in HIV pharmacology",
        "The role of therapeutic drug monitoring in the management of HIV-infected patients",
        "Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir",
        "Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia",
        "Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study",
        "Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients",
        "The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals",
        "Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients",
        "Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen",
        "Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice",
        "Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients",
        "Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (Kalephar Study)",
        "Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient",
        "Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients",
        "Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients na\u00efve for lopinavir with limited exposure to previous protease inhibitors",
        "Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir",
        "The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients",
        "Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients",
        "Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients",
        "Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens",
        "Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens",
        "Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients",
        "Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study",
        "Therapeutic drug monitoring of intracellular anti-infective agents",
        "Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy",
        "Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations",
        "J AIDS Clin Res",
        "Non-nucleoside reverse transcriptase inhibitors: A review on pharmacokinetics, pharmacodynamics, safety and tolerability",
        "Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients",
        "Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study",
        "Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study",
        "Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients",
        "HIV protease inhibitors: A review of molecular selectivity and toxicity",
        "Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens",
        "Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients",
        "A review of low-dose ritonavir in protease inhibitor combination therapy",
        "Pharmacokinetics and pharmacodynamics of gs-9350: A novel pharmacokinetic enhancer without Anti-HIV activity",
        "Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: Week 48 results",
        "Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers",
        "Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications",
        "Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection",
        "Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection",
        "Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen - ANRS 111 trial"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Kensington",
            "affilname": "The Kirby Institute",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "The HIV Netherlands Australia Thailand Research Collaboration",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nijmegen",
            "affilname": "Radboud University Medical Center",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "Amsterdam",
            "affilname": "Universiteit van Amsterdam",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "Chiang Mai",
            "affilname": "Chiang Mai University",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}